0000000000150206

AUTHOR

Ruth Uso

showing 9 related works from this author

Impact of Acute Hemoglobin Falls in Heart Failure Patients: A Population Study

2020

Aims: This study assessed the impact of acute hemoglobin (Hb) falls in heart failure (HF) patients. Methods: HF patients with repeated Hb values over time were included. Falls in Hb greater than 30% were considered to represent an acute episode of anemia and the risk of hospitalization and all-cause mortality after the first episode was assessed. Results: In total, 45,437 HF patients (54.9% female, mean age 74.3 years) during a follow-up average of 2.9 years were analyzed. A total of 2892 (6.4%) patients had one episode of Hb falls, 139 (0.3%) had more than one episode, and 342 (0.8%) had concomitant acute kidney injury (AKI). Acute heart failure occurred in 4673 (10.3%) patients, represent…

medicine.medical_specialtyAnemiaheart failurelcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineRisk of mortality030212 general & internal medicineblood lossFirst episodebusiness.industryHazard ratiolcsh:RAcute kidney injuryGeneral Medicinemedicine.diseaseanemiamortalityConfidence interval3. Good healthacute kidney injuryConcomitantHeart failurebusinesshospitalizationJournal of Clinical Medicine
researchProduct

Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study

2017

Introduction The potential impact of targeting different components of an adverse lipid profile in populations with multiple cardiovascular risk factors is not completely clear. This study aims to assess the association between different components of the standard lipid profile with allcause mortality and hospitalization due to cardiovascular events in a high-risk population. Methods This prospective registry included high risk adults over 30 years old free of cardiovascular disease (2008-2012). Diagnosis of hypertension, dyslipidemia or diabetes mellitus was inclusion criterion. Lipid biomarkers were evaluated. Primary endpoints were all-cause mortality and hospital admission due to corona…

Malelcsh:MedicineCoronary Disease030204 cardiovascular system & hematology0302 clinical medicineRisk Factors030212 general & internal medicinelcsh:ScienceStrokeeducation.field_of_studyMultidisciplinarymedicine.diagnostic_testMortality rateAbsolute risk reductionMiddle AgedLipidsHospitalizationStrokeDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular DiseasesHypertensionObesitatSERUM-LIPIDSFemalelipids (amino acids peptides and proteins)HEALTHAdultmedicine.medical_specialtyELECTRICITY GENERATING AUTHORITYRANDOMIZED CONTROLLED-TRIALSPopulationPREDICTION MODELEVENTS03 medical and health sciencesInternal medicineDiabetes mellitusmedicineMortalitatDiabetes MellitusHumansCORONARY-HEART-DISEASEOLDER-PEOPLEeducationTriglyceridesSistema cardiovascularAgedHDL CHOLESTEROLbusiness.industrylcsh:RCholesterol HDLCholesterol LDLmedicine.diseaseAttributable risklcsh:QLipid profilebusinessDyslipidemia
researchProduct

Is the Physician’s Behavior in Dyslipidemia Diagnosis in Accordance with Guidelines? Cross-Sectional Escarval Study

2013

Background: Clinical inertia has been defined as mistakes by the physician in starting or intensifying treatment when indicated. Inertia, therefore, can affect other stages in the healthcare process, like diagnosis. The diagnosis of dyslipidemia requires $ 2 high lipid values, but inappropriate behavior in the diagnosis of dyslipidemia has only previously been analyzed using just total cholesterol (TC). Objectives: To determine clinical inertia in the dyslipidemia diagnosis using both TC and high-density lipoprotein cholesterol (HDL-c) and its associated factors. Design: Cross-sectional. Setting: All health center visits in the second half of 2010 in the Valencian Community (Spain). Patient…

MaleHealth ScreeningNon-Clinical MedicineCross-sectional studyHealth Care ProvidersCardiovascularchemistry.chemical_compoundRisk FactorsOdds RatioPractice Patterns Physicians'Young adultHealth Systems StrengtheningMultidisciplinaryCommunicationQRAtrial fibrillationMiddle AgedCholesterolMedicineFemalelipids (amino acids peptides and proteins)Guideline AdherencePublic HealthResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignScienceCardiologyYoung AdultDiagnostic MedicinePhysiciansInternal medicineDiabetes mellitusmedicineHumansHealth Care QualityAgedDyslipidemiasHealth Care Policybusiness.industryCholesterolCholesterol HDLOdds ratiomedicine.diseaseMiddle ageCross-Sectional StudieschemistrySpainPreventive MedicinebusinessDyslipidemia
researchProduct

Niveles de complejidad asistencial en pacientes con códigos diagnósticos de insuficiencia cardiaca en una población

2018

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation

2022

AimsTo assess the impact of anticoagulant treatment on risk for stroke and all-cause mortality of patients with atrial fibrillation using real-world data (RWD).MethodsPatients with prevalent or incident atrial fibrillation were selected throughout a study period of 5 years. Stroke, transitory ischemic attack, hemorrhagic stroke, and all-cause mortality were identified in the claims of the electronic health records (EHRs). Subjects were classified according to the anticoagulant treatment in four groups: untreated, vitamin K antagonists (VKAs), New Oral Anticoagulants (NOACs), and antiplatelet (AP). Risk of events and protection with anticoagulant therapy were calculated by Cox proportional h…

anticoagulant therapyRC666-701VKADiseases of the circulatory (Cardiovascular) systematrial fibrillationNOACsCardiovascular MedicineantiplateletCardiology and Cardiovascular MedicinestrokemortalityOriginal ResearchFrontiers in Cardiovascular Medicine
researchProduct

Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study

2018

Introduction The potential impact of targeting different components of an adverse lipid profile in populations with multiple cardiovascular risk factors is not completely clear. This study aims to assess the association between different components of the standard lipid profile with all-cause mortality and hospitalization due to cardiovascular events in a high-risk population. Methods This prospective registry included high risk adults over 30 years old free of cardiovascular disease (2008–2012). Diagnosis of hypertension, dyslipidemia or diabetes mellitus was inclusion criterion. Lipid biomarkers were evaluated. Primary endpoints were all-cause mortality and hospital admission due to coron…

AdultMaleDeath RatesEndocrine Disorderslcsh:MedicineBlood PressureCoronary DiseaseCardiovascular Medicine030204 cardiovascular system & hematologyBiochemistryVascular Medicine03 medical and health sciencesEndocrinology0302 clinical medicinePopulation MetricsRisk FactorsMalalties ComplicacionsMortalitatMedicine and Health SciencesDiabetes MellitusHumans030212 general & internal medicinelcsh:ScienceTriglyceridesSistema cardiovascularAgedMultidisciplinaryPopulation BiologyCholesterol HDLlcsh:RBiology and Life SciencesCorrectionCholesterol LDLMiddle AgedLipidsHospitalizationStrokeCholesterolNephrologyCardiovascular DiseasesMetabolic DisordersHypertensionlipids (amino acids peptides and proteins)Femalelcsh:QBiomarkersResearch ArticlePLOS ONE
researchProduct

Complexity Levels in Patients With Heart Failure Diagnostic Codes in a Population

2018

Heart Failuremedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationClinical CodingMEDLINEGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseSeverity of Illness Index03 medical and health sciences0302 clinical medicinePredictive Value of TestsHeart failurePredictive value of testsSeverity of illnessmedicineHumansIn patientDiagnosis codeIntensive care medicineeducationbusinessRevista Española de Cardiología (English Edition)
researchProduct

Acute kidney injury in heart failure: a population study

2020

Abstract Aims The objective of the present study is to assess the prognostic value of acute kidney injury (AKI) in the evolution of patients with heart failure (HF) using real‐world data. Methods and results Patients with a diagnosis of HF and with serial measurements of renal function collected throughout the study period were included. Estimated glomerular filtration rate (GFR) was calculated with the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration). AKI was defined when a sudden drop in creatinine with posterior recovery was recorded. According to the Risk, Injury, Failure, Loss, and End‐Stage Renal Disease (RIFLE) scale, AKI severity was graded in three categories: risk [1.5‐…

medicine.medical_specialtyRenal functionHeart failure030204 cardiovascular system & hematologyRisk of hospitalization03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOriginal Research ArticlesRisk of mortalitymedicineHumansDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleRetrospective StudiesFirst episodeCreatininebusiness.industryIncidence (epidemiology)Hazard ratioAcute kidney injurymedicine.disease3. Good healthAcute kidney injurychemistryRisk of mortalityCreatinineRC666-701CardiologyFemaleCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateRenal functionESC Heart Failure
researchProduct

Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain.

2019

Abstract Background Drug treatment for secondary prevention of cardiovascular disease is recommended by guidelines, but it is not always followed in real life. This study wanted to assess the size of this gap and its impact on mortality in subjects after a cardiovascular event (MACE). Methods Patients with any of MACE in the period from January 1st 2011 to December 31st 2013, and more than one year of follow-up were selected from population of the Valencian Community. Drugs for secondary prevention were antiplatelets, renin-angiotensin system blockers and statins. Assessment of treatment was performed one year after the initial event. Mortality risk was assessed using Cox by the number of d…

DrugMalemedicine.medical_specialtyMedication Therapy Managementmedia_common.quotation_subjectmedicine.medical_treatmentPopulationMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsDisease030204 cardiovascular system & hematologyRevascularizationRisk Assessment03 medical and health sciencesAngiotensin Receptor Antagonists0302 clinical medicineInternal medicinemedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctioneducationStrokemedia_commonAgededucation.field_of_studybusiness.industryConfoundingmedicine.diseaseSurvival AnalysisProfessional Practice GapsStrokeSpainFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessMacePlatelet Aggregation InhibitorsInternational journal of cardiology
researchProduct